SCHEDULE: Farallon Capital Reports 5.6% Stake in Tyra Biosciences

Farallon Capital and its affiliates have disclosed a collective beneficial ownership of 5.6% in Tyra Biosciences, Inc. common stock.

Summary

• Farallon Capital Partners, L.P. and its affiliated entities (collectively, the "Reporting Persons") have filed a Schedule 13G.
• The filing reports beneficial ownership of common stock in Tyra Biosciences, Inc. (CUSIP: 90240B106).
• The aggregate amount beneficially owned by the Farallon Individual Reporting Persons is 2,984,818 shares.
• This aggregate ownership represents 5.6% of Tyra Biosciences, Inc.'s class of common stock.
• The shares are held across various Farallon funds, including Farallon Capital Partners, L.P., Farallon Capital Institutional Partners, L.P., Farallon Capital Offshore Investors II, L.P., and others.
• Farallon Partners, L.L.C., as the general partner for most of the funds, beneficially owns 2,828,865 shares, representing 5.3% of the class.
• The filing states that the securities were not acquired and are not held for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It is a routine regulatory disclosure of passive beneficial ownership and does not contain information that would inherently sway sentiment positively or negatively.

Positives

• A significant institutional investor, Farallon Capital, maintains a notable stake in Tyra Biosciences, indicating continued interest in the company.

Negatives

• The filing is a routine disclosure of passive ownership and does not contain any negative operational or financial news.

Risks

• The filing itself does not introduce new risks but is a disclosure of existing ownership. The disclaimer of intent to influence control means the company should not expect activist pressure from this stake.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that institutional filings like this Schedule 13G are standard disclosures. Farallon Capital is a prominent investment firm, and its reported stake in Tyra Biosciences reflects its investment strategy in the biotechnology sector. This type of filing typically does not signal a change in industry trends but rather an investor's position within it.

Comparison to Industry Standards

• This filing is a standard Schedule 13G, which is a routine disclosure for institutional investors acquiring more than 5% of a company's stock with passive intent. It aligns with regulatory requirements for transparency in beneficial ownership.
• The reported 5.6% stake is a significant, but not controlling, position, common for large institutional funds like Farallon Capital when investing in public companies, particularly in sectors like biotechnology where growth potential is often a key driver.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional holder's stake, confirming a large investor's position in the company.
• Management: Awareness of a substantial passive investor, but no indication of intent to influence control or operations.

Key Dates

Keywords

Tyra Biosciences, Farallon Capital, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology, SEC Filing